Pseudoprogression Shown on 18F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer Metastatik Mesane Kanserli Bir Olguda Pembrolizumab Tedavisi Sonrası 18F-FDG PET/BT’de Gösterilen Psödoprogresyon
Molecular Imaging and Radionuclide Therapy, cilt.34, sa.1, ss.70-72, 2025 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 34 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.4274/mirt.galenos.2024.47135
- Dergi Adı: Molecular Imaging and Radionuclide Therapy
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.70-72
- Anahtar Kelimeler: Immunotherapy, pseudoprogression, bladder cancer, pembrolizumab, PET/CT
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
A 57-year-old man diagnosed with a metastatic bladder tumor was initiated on pembrolizumab treatment. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging performed to evaluate treatment response showed numerical-dimensional and metabolic increase in the metastatic lesions. In the 18F-FDG PET/CT imaging performed 8 weeks later due to suspicion of pseudoprogression, a significant regression of the lesions was observed, and the patient was diagnosed with pseudoprogression. Pseudoprogression should be kept in mind when 18F-FDG PET/CT is performed after the use of immunotherapy, and evaluation with follow-up PET/CT is recommended to confirm that the patient has hyperprogression or pseudoprogression.